Omeros (NASDAQ:OMER)

CAPS Rating: 2 out of 5

Results 1 - 12 of 12

Recs

0
Member Avatar Bobmoll36 (44.95) Submitted: 11/17/2014 1:38:23 PM : Outperform Start Price: $19.69 OMER Score: +16.44

in at 13. Rising well. good drug history

Recs

0
Member Avatar fdgaley (< 20) Submitted: 8/12/2014 5:13:29 PM : Outperform Start Price: $12.79 OMER Score: +76.71

Great Pipeline.

Recs

0
Member Avatar griderX (97.27) Submitted: 6/3/2014 10:12:34 AM : Outperform Start Price: $11.43 OMER Score: +95.21

Speculative Buy List

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 4/8/2014 12:34:14 AM : Outperform Start Price: $11.00 OMER Score: +98.19

Perhaps the secret PDUFA date for Omidria is keeping Omeros off run-up traders' catalyst calendars. The stock has been decidedly weak ahead of the FDA approval decision, which I project will occur in early June. Meanwhile, Omeros is attempting to escape from their grimy repurposer past with sexier new chemical entities OMS721 and OMS824. With a powerful catalyst approaching and a newly strengthened pipeline, Omeros could be a force to reckon with if the biopharma sector snaps out of its recent funk.

Recs

0
Member Avatar kcprojects (< 20) Submitted: 12/19/2013 6:41:16 PM : Outperform Start Price: $10.16 OMER Score: +113.35

FDA approval

Recs

0
Member Avatar pcguy (< 20) Submitted: 11/23/2013 2:42:56 AM : Outperform Start Price: $7.20 OMER Score: +207.23

FDA approval.

Recs

0
Member Avatar dwayneshimizu (59.68) Submitted: 9/25/2013 4:10:23 AM : Outperform Start Price: $6.99 OMER Score: +215.70

medical.

Recs

0
Member Avatar stover87 (< 20) Submitted: 2/4/2013 10:13:54 AM : Outperform Start Price: $5.61 OMER Score: +274.85

Q! 2013 NDA filing and mid 2013 filing in europe, looking very postive and phase 3 results exceeded expectations.

Recs

0
Member Avatar fox2man2 (< 20) Submitted: 10/6/2012 12:38:50 AM : Outperform Start Price: $10.29 OMER Score: +82.94

I believe OMER will outperform the S&P 500 by a considerable amount. I encourage Fools to go to its website and read about recent developments in its propieteray medical programs. That is a 15 minute task and well worth one's time. OMER has no income at this time, but expects approval of two drugs in 2013, one for arthroscopic knee surgery and a second for eye surgery. Daily trading volume has been small, however, and this should be considered by prospective investors.

Recs

0
Member Avatar SeaKeaFool (< 20) Submitted: 2/10/2012 2:39:23 AM : Outperform Start Price: $6.32 OMER Score: +211.61

G Protein Coupled Receptor cells in portfolio are potentially worth far more than current market value of the company. These are new intellectual properties that add to the value of the drugs in clinical trials. Can be volatile, but long term outlook is good.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 4/1/2011 11:03:52 AM : Underperform Start Price: $5.17 OMER Score: -292.74

this a warning for all beginners! why? so you can put the money in my stocks and so drive my winnings

Recs

0
Member Avatar cwstrand (< 20) Submitted: 10/21/2009 12:16:46 AM : Outperform Start Price: $6.85 OMER Score: +148.27

The patents this company holds are incredible. The breakthrough in patient treatment for pain post-surgery (in clinical trials) is outstanding for arthro, eye, uro, etc. are oustanding. Once any of the trials, in various phases now, hits, this will blow sky high.

Results 1 - 12 of 12

Featured Broker Partners


Advertisement